Industry news

Opthea Pioneering Advances in Retinal Therapeutics

news,
AIBLABS,
September 14, 2023
This article elucidates the ground-breaking endeavours of Opthea in retinal therapeutics. It emphasises the latest developments in their retinal medicines, focusing particularly on the revolutionary therapy, OPT-302, for Wet Age-related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME). This piece concludes with an overview of Opthea's contributions to the American Society of Retina Specialists (ASRS) 2023 event and their future outlook in this field.

Race Strikes Global Licensing Agreement with City of Hope, Securing FTO Intellectual Property Access

news,
AIBLABS,
September 14, 2023
In a historic move, Race has concluded a global licensing agreement with City of Hope, securing exclusive rights to access its FTO intellectual property (IP). This partnership promises to yield a wealth of opportunities, further cementing Race's position in the global market and opening new avenues for the application of City of Hope's cutting-edge IP.

Revolution in UTI Treatment

news,
AIBLABS,
September 14, 2023
Recce Pharmaceuticals, the Australian biotech pioneer, has announced the initiation of the Phase I/II clinical trials for their novel antibiotic compound, RECCE® 327. The first cohort has been dosed in this potentially game-changing study, focusing on the treatment of Urinary Tract Infections (UTIs).
Copyright © 2023 AIBLABS.org.au. All Rights Reserved